New hope for tough MDS cases? small trial tests Triple-Drug attack
NCT ID NCT05564650
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This early-phase study tested a new drug combination (navitoclax, venetoclax, and decitabine) in 6 adults with high-risk myelodysplastic syndrome (MDS) that returned or didn't respond to initial treatment. The main goals were to find the safest dose and check for side effects. This research aims to improve options for people with hard-to-treat MDS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.